Inuvair Nexthaler

Beclometasone dipropionate and Formoterol fumarate, the active ingredients in Inuvair Nexthaler, are an inhaled corticosteroid/long‑acting β2‑agonist combination presented as a dry powder inhaler for inhalation use. They work together to reduce airway inflammation and to relax bronchial smooth muscle, providing maintenance therapy for asthma and chronic obstructive pulmonary disease in adult patients.

GNH USA supplies Inuvair Nexthaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance for global distribution.

Inuvair Nexthaler combines an inhaled corticosteroid with a long‑acting β2‑agonist to treat chronic airway diseases.

Asthma: maintenance therapy that improves symptom control and reduces exacerbations. COPD: maintenance treatment that enhances lung function and lowers the risk of flare‑ups. Chronic bronchitis (as part of COPD): helps control airway inflammation and provides bronchodilation for better airflow. Severe asthma: adjunct therapy when high‑dose inhaled corticosteroid alone is insufficient.

Inhalation of Inuvair Nexthaler may be associated with a range of adverse reactions.

Common Side Effects: - Throat irritation - Hoarseness - Oral candidiasis (thrush) - Cough

Serious or Rare Side Effects: - Paradoxical bronchospasm - Adrenal suppression - Severe allergic reactions (anaphylaxis)

Use of Inuvair Nexthaler requires careful clinical assessment and patient education.

Assess infection status: avoid initiating during active respiratory infections. Monitor for oral thrush: rinse mouth after each inhalation. Evaluate cardiovascular health: use with caution in patients with arrhythmias or severe hypertension. Use lowest effective dose: adjust based on clinical response and guideline recommendations. Discontinue gradually: abrupt cessation may lead to loss of asthma control. Store at ambient temperature: keep in original container, protect from moisture and heat.

Inuvair Nexthaler may interact with other medicines; review patient medication lists regularly.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator effect and precipitate bronchospasm. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase systemic exposure to beclometasone. - Concomitant use of other inhaled corticosteroids: risk of additive systemic steroid effects.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may enhance hypokalaemia risk from β2‑agonist activity. - Theophylline: β2‑agonist can increase theophylline plasma levels. - Non‑selective NSAIDs: may exacerbate bronchospasm in sensitive individuals.